Acer Therapeutics Inc. (NASDAQ:ACER) does about 426.37K shares in volume on a normal day but saw 2162406 shares change hands in Friday trading. The company now has a market cap of 53.78M USD and an enterprise value of about $55.52M. Its current market price is $3.85, marking a decrease of -26.67% compared to the previous close of $5.25. The 52 week high reached by this stock is $7.25 whilst the lowest price level in 52 weeks is $1.08. The script in recent trading has seen the stock touch a high of $4.9429 and a low of $3.7802.
Acer Therapeutics Inc. (ACER) has a 20-day trading average at $4.16 and the current price is -46.90% off the 52-week high compared with 256.48% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.65 and its 200-day simple moving average is $3.40. If we look at the stock’s price movements over the week, volatility stands at 17.26%, which decreases to 13.28% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 46.22 to suggest the stock is neutral.
5 analysts observing the Acer Therapeutics Inc. (ACER) stock have set the 12-month price targets for the company’s shares at between $10.00 and $10.00. The median price target is 61.5% away from the current levels at $10.00.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 3 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 26, 2019 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $55 and $10. William Blair downgraded the stock to “Mkt Perform” from Outperform on June 25, 2019 at a price target of .
The current price level is -6.84%, 6.05%, and 13.29% away from its SMA20, SMA50, and SMA200 respectively, with the ACER price moving below the 50-day SMA on August 14. Acer Therapeutics Inc. (ACER) stock is down -28.84% over the week and 14.93% over the past month. Its price is -3.99% year-to-date and 97.44% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.56 below consensus estimates by -$0.18. The company’s next earnings report is expected on 11/17/2020, with forecasts estimating quarterly EPS at -$0.44 and -$1.84 for whole year. ACER’s earnings per share are forecast to grow by 36.80% this year and 18.50% over next year.
Its 12-month price target is $10.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $10.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $10.00.
Outstanding shares total 10.37M with insiders holding 24.64% of the shares and institutional holders owning 51.93% of the company’s common stock. The company has a return on equity of -127.00%. The beta has a value of 1.99. Price to book ratio is 3.56.
According to a U.S. Securities and Exchange Commission filing, Federated Hermes MDT Small Cap Gr has added its position in Acer Therapeutics Inc. (ACER) to 146,096 shares, mirroring a recent increase by 63.04%. Federated Hermes MDT Small Cap Gr added 56487.0 shares of Acer Therapeutics Inc. common stock bringing its total worth to about $0.54 million at the end of recent close, SEC documents show. Federated Hermes MDT Small Cap Gr isn’t the only investment manager who changed stakes and is followed by BlackRock Strategic Fds – Americ, which sold off 0.0 shares to end up with 99,794 shares worth $0.37 million. Vanguard Total Stock Market Index cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.69% position in Acer Therapeutics Inc. thanks to 70268.0 shares amounting to $0.26 million.